Logo Image
News|Webcasts|May 21, 2024

Overcoming AAV Aggregate Analysis Challenges Using a Novel Size Exclusion Column to Determine CQAs

Author(s)Phenomenex

Webinar Date/Time: Thu, Jun 6, 2024 11:00 AM EDT

Register to learn about overcoming AAV aggregate analysis challenges using a novel SEC chemistry. Maximize aggregate/monomer resolution, reduce sample consumption and run times, and method optimization best practices across buffer systems and serotypes.

Register Free:
https://www.chromatographyonline.com/lcgc_w/aggregate-analysis

Event Overview:

Aggregate analysis of Adeno Associated Virus (AAV) is crucial for quality assessment and currently presents various challenges including long run times, high volume sample consumption where sample quantities are limited, and accurate quantitation of monomer and aggregate species. In this webinar, Senior Research Scientist Shilin Cheung, will review optimization of high throughput size exclusion chromatography methods using a novel 700 Å pore size SEC chemistry to reduce sample consumption and run times. Additionally, method versatility with multiple mobile phase conditions utilizing various detectors across several AAV serotypes will be explored.


Key Learning Objectives:

  • Learn how a novel 700 Å pore size SEC chemistry improves lab throughput and reduces sample consumption for AAV aggregate analysis.
  • Review of method optimization best practices to maximize AAV monomer/aggregate resolution.
  • Learn how selecting appropriate particle chemistry, pore size and hardware improves SEC performance for AAV analysis.

Who Should Attend:

  • Biopharmaceutical scientists who want to improve chromatographic performance and throughput of AAV analysis.
  • Protein scientists interested in reducing sample consumption of AAVs.
  • Process development scientists evaluating alternate SEC technologies to improve AAV aggregate data quality.


Speakers:

Dr. Shilin Cheung
Sr. Research Scientist
Phenomenex Inc.

Dr. Shilin Cheung received her BS (2006) and Ph.D. (2012) in Bioanalytical Chemistry from the University of Toronto. She has developed, qualified, and validated innovative analytical methods in CE based microfluidics, automated low volume UV-vis spec., and UHPLC assays. Her methods have been applied to manufacturing process developments, formulation and stability and DS/DP characterization and specification testing. At Phenomenex she is focused on developing fit for purpose analytical methods to help advance developments in gene therapeutics.

Ramkumar Dhandapani, PhD
Sr Product Manager
Phenomenex Inc

Register Free:
https://www.chromatographyonline.com/lcgc_w/aggregate-analysis

Related to this article

View more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more